Sartorius Stedim Biotech completed the acquisition of Xell for €50m.

Sartorius Stedim Biotech, a life science company, completed the acquisition of Xell, a provider of cell culture media and feed solutions, for €50m. "With this acquisition, we are expanding our current media offering specifically by specialized media for manufacturing viral vectors and, additionally, in the area of media analytics. At the same time, we are accelerating the expansion of our production network in this fast-growing area. I would like to cordially welcome the Xell team to Sartorius Stedim Biotech and am looking forward to our collaboration in this demanding time," René Fáber, Sartorius Stedim Biotech Member of the Board of Directors.